Cargando…

Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS

Detalles Bibliográficos
Autores principales:	Gladstone, Douglas E, D'Alessio, Franco, Howard, Christopher, Lyu, Mi-Ae, Mock, Jason R., Gibbs, Kevin W., Abrams, Darryl, Huang, Meixian, Zeng, Ke, Herlihy, James P., Castillo, Sergio T., Bassett, Roland, Sadeghi, Tara, Parmar, Simrit, Flowers, Christopher R., Mukherjee, Siddhartha, Schoenfeld, David, Thall, Peter F., Slutsky, Arthur S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043947/ https://www.ncbi.nlm.nih.gov/pubmed/36961352 http://dx.doi.org/10.1182/bloodadvances.2022009619

Ejemplares similares

Randomized, Multi-Center, Double-Blinded, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) in the Treatment of COVID-19 Induced ARDS. (RESOLVE Trial)
por: Gladstone, Douglas E, et al.
Publicado: (2021)

Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus
por: Lyu, Mi-Ae, et al.
Publicado: (2023)

Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells
por: Zeng, Ke, et al.
Publicado: (2023)

We’ve never seen a patient with ARDS!
por: Vincent, Jean-Louis, et al.
Publicado: (2020)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

ECMO for severe ARDS: systematic review and individual patient data meta-analysis
por: Combes, Alain, et al.
Publicado: (2020)

COVID-19 ARDS: getting ventilation right – Authors' reply
por: Barbaro, Ryan P, et al.
Publicado: (2022)

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution
por: Kellner, Joshua N., et al.
Publicado: (2018)

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS
por: Ferrando, Carlos, et al.
Publicado: (2020)

Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter?
por: Goligher, Ewan C., et al.
Publicado: (2020)

ECMO for severe ARDS associated with COVID-19: now we know we can, but should we?
por: Shekar, Kiran, et al.
Publicado: (2020)

Correction to: Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS
por: Ferrando, Carlos, et al.
Publicado: (2020)

0988. Human neutrophil peptides play an important role in the pathogenesis of ARDS
por: Pozzi, F, et al.
Publicado: (2014)

Current and evolving standards of care for patients with ARDS
por: Menk, Mario, et al.
Publicado: (2020)

In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals
por: Li, Li, et al.
Publicado: (2022)

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen
por: Kellner, Joshua N., et al.
Publicado: (2018)

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
por: Zarrabi, Morteza, et al.
Publicado: (2023)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Hemodynamic Implications of Prone Positioning in Patients with ARDS
por: Lai, Christopher, et al.
Publicado: (2023)

More of the Gut in the Lung: How Two Microbiomes Meet in ARDS
por: Mukherjee, Samiran, et al.
Publicado: (2018)

The rise and fall of β-agonists in the treatment of ARDS
por: Bassford, Christopher R, et al.
Publicado: (2012)

Evaluation of PEEP and prone positioning in early COVID-19 ARDS
por: Mittermaier, Mirja, et al.
Publicado: (2020)

Corticosteroids in ARDS
por: Kuperminc, Emmanuelle, et al.
Publicado: (2023)

The incidence of ARDS, interim results of the East Anglian ARDS Registry
por: Dixon, JM, et al.
Publicado: (2000)

What’s new in ARDS: ARDS also exists in resource-constrained settings
por: Riviello, Elisabeth D., et al.
Publicado: (2016)

How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study
por: Hraiech, Sami, et al.
Publicado: (2017)

COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study
por: Shi, Rui, et al.
Publicado: (2021)

Arde la imagen /
por: Didi-Huberman, Georges
Publicado: (2012)

Arde el mar /
por: Gimferrer, Pere, 1945-
Publicado: (1997)

Steroids in late ARDS?
por: Wajanaponsan, Non, et al.
Publicado: (2007)

Steroids in early ARDS?
por: Aldabbagh, Tarek, et al.
Publicado: (2007)

Arde la imagen /
por: Didi-Huberman, Georges
Publicado: (2019)

The ARDS Support Center
por: Raggio, Michael J, et al.
Publicado: (2003)

Regional physiology of ARDS
por: Gattinoni, Luciano, et al.
Publicado: (2017)

Myorelaxants in ARDS patients
por: Hraiech, Sami, et al.
Publicado: (2020)

Tuberculosis complicated by ARDS
por: Arevalo-Lorido, J. C., et al.
Publicado: (2001)

Future therapies for ARDS
por: Curley, Gerard F., et al.
Publicado: (2014)

Fibrinolytics as an ARDS Salvage Option: Promising, But ARDS Prevention Options Are Needed Urgently
por: Cap, Andrew P.
Publicado: (2022)

Cardiovascular Subphenotypes in ARDS: Diagnostic and Therapeutic Implications and Overlap with Other ARDS Subphenotypes
por: Chotalia, Minesh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ifugsdepce892m7p0dsj6kmki